Followers | 145 |
Posts | 27558 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Thursday, September 29, 2022 11:45:43 AM
Sep. 29, 2022 11:08 AM ETGamida Cell Ltd. (GMDA)
By: Dulan Lokuwithana, SA News Editor
Israel-based biotech Gamida Cell Ltd. (NASDAQ:GMDA) announced Thursday that its stem cell therapy candidate omidubicel led to clinical benefit at three years in a group of patients with blood cancer who typically have a poor prognosis.
The analysis included long-term follow-up data from 105 patients who underwent omidubicel transplants between 2006-2020.
The company said that the study presented at the Annual Meeting of the Society of Hematologic Oncology indicated 63% overall survival and 56% disease-free survival at three years, in addition to long-term blood cell formation and immunity.
Another 108-patient study demonstrated that omidubicel could lead to a higher health-related quality of life than umbilical cord blood transplantation.
In August, GMDA announced that the FDA granted priority review for omidubicel as a treatment for patients with blood cancers who need an allogenic hematopoietic stem cell transplant. The regulator is expected to make a decision by Jan. 30.
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM